Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 1.01
Pyxis Oncology entered into a securities purchase agreement on June 30, 2026, to issue 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number of shares at $3.289 per share, generating approximately $50 million in gross upfront proceeds with potential additional $64 million if warrants are exercised. This private placement significantly extends the company's cash runway into Q2 2027 and funds advancement of its lead clinical program.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 8.01
The disclosure reports exercise of warrants resulting in issuance of 13,619,377 shares of common stock to OC III LFE II, LP on June 30, 2026. This represents a substantial dilutive issuance that increased outstanding shares from an implied ~19.2 million to 32.8 million shares (approximately 71% dilution), materially affecting shareholder ownership and voting power. The magnitude and nature of the warrant exercise constitute a material capital event requiring disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 1.01
Enanta Pharmaceuticals entered into an Open Market Sale Agreement with Jefferies LLC authorizing the sale of up to $75 million in common stock through an at-the-market (ATM) offering. This is a dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a significant capital-raising event for the company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-07-02
EX-99.1
This is an ASX Appendix 2A application for quotation of 34,824 ordinary shares issued on vesting of 54,480 performance rights under an employee incentive scheme on 2–3 July 2026. While the immediate issuance is modest in absolute terms, it represents a dilutive equity event (conversion of unquoted performance rights into quoted ordinary shares) that increases the share count and would be material to a reasonable investor assessing capital structure and dilution. The document confirms the securities rank equally with existing ordinary shares and notes substantial unquoted convertible securities (45.2M convertible notes, 35M convertible debentures) that pose future dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 8.01
ITG, Inc. completed an initial public offering on July 2, 2026, issuing 19,512,196 shares of Class A Common Stock at $16.00 per share, with underwriters exercising an option to purchase an additional 2,926,829 shares. The proceeds were used to purchase LLC interests from ITG Parent, which then repaid debt facilities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
ITG, Inc. issued over 101 million shares of Class A and Class B Common Stock to Oaktree Blocked Fund, Oaktree Aggregator, and ITG Management Holdings, LLC on July 1, 2026, in reliance on Section 4(a)(2) exemption from Securities Act registration as part of a restructuring or recapitalization transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 3.02
CID Holdco issued a $500,000 secured convertible note to a new investor in reliance on Section 4(a)(2) and Regulation D exemptions, providing additional capital through an unregistered private placement of a dilutive equity instrument.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-02
Item 1.01
Tenon Medical completed a registered public offering on July 1, 2026, issuing 11,052,631 shares of common stock (or pre-funded warrants) and 13,263,159 common stock purchase warrants, raising $4.2 million in gross proceeds. The offering includes warrants exercisable at $0.38 and $0.001 per share, with proceeds to be used in part for repayment of convertible notes, reflecting significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
ISQ Open Infrastructure Co LLC completed unregistered sales of equity securities totaling $31.9 million across Series I and Series II share classes as of June 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 8.01
The Company sold 76.35 million shares of Common Stock over two days (June 30 and July 1, 2026) pursuant to an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners, raising approximately $7.11 million in gross proceeds. This represents a dilutive issuance that increased outstanding shares from 21.5 million to 97.9 million—a 355% increase—which is material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 3.02
Elroy Air issued unregistered convertible promissory notes and warrants to institutional investors in a pre-funded offering under Section 4(a)(2) of the Securities Act as part of the business combination transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-02
Item 1.01
OS Therapies entered into a securities purchase agreement on June 30, 2026, to issue a $10 million senior secured convertible promissory note, 275,000 commitment shares, and a five-year warrant for 1,750,000 shares to Leonite Fund I, LP in a private placement. The transaction includes anti-dilution provisions and beneficial ownership limitations tied to NYSE American stockholder-approval thresholds, with the company obligated to seek stockholder approval within 90 days.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-02
The Company issued 2,400,000 Class B ordinary shares to the CEO/Chairman's affiliate (Lianyue Holding Limited) at $0.165 per share for gross proceeds of $396,000 under Regulation S. This is an unregistered equity issuance that is dilutive to existing shareholders; post-closing, the CEO's affiliate controls approximately 97.69% of aggregate voting power, representing a material concentration of control and significant dilution to public shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 1.01
Peraso entered into a Common Stock Purchase Agreement with Roth Principal Investments establishing a committed equity facility (CEF) allowing the Company to sell up to $25 million of newly issued common stock at its discretion over 36 months, subject to Nasdaq rule limitations capping issuance at 19.99% of outstanding shares unless stockholder approval or a price threshold is met.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 1.01
The Company entered into a securities purchase agreement to issue 400 shares of Series F Convertible Preferred Stock (convertible at $0.50/share) and 200,000 commitment shares of common stock for $400,000 in an unregistered private placement relying on Section 4(a)(2) and Rule 506(b), representing significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 3.02
The Company issued approximately 1.5 million shares of unregistered equity securities in late June and early July 2026, including 150,000 restricted shares to a consultant, 400,000 option shares to consultants, 200,000 common shares for a waiver, and 750,000 restricted shares to consultants, all in reliance on Section 4(a)(2) and Rule 506 exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
FreeCast entered into a Securities Purchase Agreement on June 30, 2026, closing July 2, 2026, for a private placement of 4,666,667 shares of Class A common stock and pre-funded warrants to purchase 3,243,807 additional shares, raising approximately $23.7 million in gross proceeds. The securities were sold without registration under Section 4(a)(2) of the Securities Act and Regulation D to accredited investors. This is a classic dilutive equity issuance—unregistered private placement raising capital through equity dilution—disclosed under Item 1.01 (Material Definitive Agreement) and Item 3.02 (Unregistered Sale of Equity Securities).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
Partners Group Lending Fund, LLC completed an unregistered private placement of 16,233 Class M units for $24,540 to accredited investors pursuant to Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-02
Item 1.01
The filing discloses entry into a Registration Rights Agreement in connection with a private offering of common stock under Rule 506(b), with a subsequent amendment extending the registration filing deadline. This represents a dilutive equity issuance to private investors. While the core transaction (the private offering itself) was previously reported on June 5, 2026, this Item 1.01 filing documents the material definitive agreement governing resale registration rights, which is a key component of the private placement structure and would materially affect shareholder interests through dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
The Company entered into warrant exercise inducement agreements resulting in the issuance of new unregistered warrants to purchase 5,580,680 shares of common stock in a private placement, generating $4.5 million in gross proceeds and creating substantial future dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
DNA X, Inc. entered into a securities purchase agreement on June 29, 2026 to issue 1,346,531 shares of Series B Convertible Preferred Stock in a private placement for $8.1 million (consisting of $5.0 million cash and $3.1 million debt cancellation) to DNA Holdings, a related party. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Material Definitive Agreement), and notes the shares will convert to Common Stock upon stockholder approval, creating significant dilution. The transaction also includes 2,494,000 additional Common Stock shares to be issued to consultants (DNA Holdings, Scott Walker, and Brock Pierce) contingent on stockholder approval, further evidencing dilutive equity issuance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-07-02
EX-99.1
Lucas GC announced termination of an At-the-Market Offering Agreement (ATM) with Maxim Group LLC for up to $20 million in Class A ordinary shares and discontinuation of a proposed public offering of Class A ordinary shares, ordinary warrants, and pre-funded warrants. While the announcement is of a *termination* rather than an issuance, the exhibit discloses the existence and scope of dilutive financing programs that were previously announced and now cancelled. The material event is the company's decision to abandon these equity-raising mechanisms in light of market conditions, which affects investor assessment of the company's capital strategy and liquidity position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
The filing discloses an unregistered private placement of convertible notes ($200,000 principal in this closing, $2,050,000 aggregate to date) and warrants (20,000 shares in this closing, 205,000 aggregate to date) under Section 4(a)(2) and Regulation D Rule 506(b). Item 3.02 explicitly confirms the unregistered sale of equity securities. The convertible notes convert into common stock at $1.60/share and the warrants are exercisable at $1.75/share, creating significant dilution to existing shareholders. This is a classic dilutive capital raise by a small-cap company (emerging growth company status noted).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
The filing discloses a registered direct offering of 11,038,767 shares of Class A common stock at $0.165 per share, closing on June 30, 2026, generating approximately $1.82 million in gross proceeds. The offering was made to accredited investors under Section 4(a)(2) and Regulation D, with the securities issued pursuant to a shelf registration statement. This is a material dilutive equity issuance that increases the company's share count and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-02
The filing discloses a securities purchase agreement with Streeterville Capital for up to $10 million in Pre-Paid Purchases of Class A common stock, with an initial closing of $2.19 million in principal amount plus 450,000 pre-delivery shares. The transaction includes unregistered equity issuances under Section 4(a)(2) and Rule 506(b), and requires shareholder approval to exceed Nasdaq Rule 5635(d) limits. While the filing also involves debt-like instruments (Pre-Paid Purchases with interest and maturity), the core material event is the dilutive equity issuance to raise capital, which is the primary mechanism and focus of the transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
The filing discloses an unregistered private placement of 850,000 shares of restricted common stock at $0.32 per share for $272,000 to an accredited investor, claimed under Section 4(a)(2) and Rule 506 of Regulation D. This is a classic dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure, particularly for a small-cap emerging growth company like Mangoceuticals.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-02
The filing discloses an unregistered issuance of 3,500 shares of newly created Series A Preferred Stock in exchange for cancellation of $3.5 million of a pre-paid purchase obligation. The Exchange Shares were issued pursuant to Section 3(a)(9) of the Securities Act and have not been registered, representing a dilutive equity issuance. While structured as an exchange rather than a cash raise, this is a material capital restructuring that dilutes common shareholders' interests and subordinates their rights to the senior preferred stock with 9% annual preferred returns and liquidation preferences.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
The filing discloses a Letter Agreement dated June 29, 2026, under Item 1.01 and Item 3.02, involving the issuance of 255,267 shares of Common Stock from abeyance, a pre-funded warrant covering 251,987 shares, and a new warrant to purchase 1,268,135 shares at $2.14 per share. These are unregistered equity issuances (exempt under Section 4(a)(2) and Regulation D) that are dilutive to existing shareholders and represent a material capital structure transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
FatPipe Inc entered into an At-The-Market (ATM) Sales Agreement with H.C. Wainwright & Co. on July 2, 2026, authorizing the sale of up to $10,000,000 in common stock shares. This is a classic dilutive equity issuance disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The ATM structure allows the company to sell shares opportunistically at market prices, which is material to investors as it signals potential capital raising and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
The Company completed an unregistered private placement of 352,179 Class J common shares for approximately $7.1 million under Section 4(a)(2) and Regulation D Rule 506, and issued 3,259.24 Class E common shares to an affiliate as payment for advisory fees, representing a significant dilutive equity issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 8.01
Circle Internet Group entered into token purchase agreements on June 29-30, 2026 to issue and sell 67.5 million ARC tokens to institutional investors in a private placement exempt from registration under Section 4(a)(2) and Regulation D Rule 506(c), generating approximately $20.25 million in gross proceeds at $0.30 per token. This is a classic private placement of equity-like securities (tokens) to raise capital, materially dilutive to existing token holders and significant to investor assessment of the company's capitalization and financing activities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-02
Item 1.01
The Company is offering and selling new series of Class I Shares (redesignated as Class I-Series 1) and three new designated share classes (Class I-Series 2, 3, and 4) to accredited investors in a private placement exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, which will materially affect existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-02
Item 1.01
The Company is conducting a continuous private offering of new share series (Class I-Series 2, 3, and 4 Shares) to accredited investors under Section 4(a)(2) and Rule 506(b), exempt from registration. Entry into material definitive agreements (Second Amended and Restated Management Agreement and Amended and Restated Dealer-Manager Agreement) facilitates this unregistered equity issuance, which will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-01
Item 3.02
FMC entered into a definitive Stock Purchase Agreement with Tessenderlo Group for an unregistered equity investment of $403.2 million (approximately 20% ownership post-closing) at $13.30 per share. The transaction includes governance rights for Tessenderlo (board seat nomination, preemptive rights, standstill provisions) and enables FMC to achieve approximately $1 billion in debt paydown.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 8.01
Eos Energy issued 13,683,634 shares of common stock and 6,004,378 warrants in a registered direct offering to Hudson Bay Master Fund Ltd. on July 1, 2026. The offering was conducted pursuant to a Form S-3 registration statement and prospectus supplement, making this a registered equity issuance that is dilutive to existing shareholders. The substantial share count and warrant issuance represent a material capital-raising event that would affect investor assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
GreenPower announced completion of the third tranche of Series A Convertible Preferred Shares in a private placement for US$1,425,000 gross proceeds, with the shares convertible into common shares at a specified conversion rate. The Company also amended the underlying Securities Purchase Agreement to increase the aggregate stated value by US$2 million. This is a dilutive equity issuance that raises capital through convertible securities, a material event affecting shareholder equity and ownership structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-01
EX-99.7
TotalEnergies issued 5,548,563 new shares on June 26, 2026, through a capital increase reserved for employees at €62.00 per share, raising €310.5 million and increasing employee shareholders' stake to 7.6% of share capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
NN Inc. entered into a Securities Purchase Agreement on June 30, 2026, to sell 24,509,804 shares of common stock in a private placement at $3.06 per share, generating $75.0 million in gross proceeds. The unregistered private placement under Section 4(a)(2) of the Securities Act and Regulation D is material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
The Sponsor purchased 7,466,667 warrants at $1.50 per warrant for $11.2 million in proceeds concurrent with the IPO, representing a material private placement of unregistered equity securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
Vishay entered into an underwriting agreement on June 29, 2026 to offer and sell 15,000,000 shares of common stock at $50 per share, with underwriters exercising a 30-day option for an additional 2,250,000 shares on June 30, 2026, generating approximately $830.3 million in net proceeds for growth initiatives and debt reduction.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-01
EX-99.1
IM Cannabis announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor. The July Note is convertible into common shares at a price of US$0.152 per share (or 90% of a 20-day VWAP floor), and the company also issued 1,483,386 warrants exercisable at C$0.22. This is a classic dilutive equity issuance—a private placement of convertible securities that will result in the issuance of common shares upon conversion and warrant exercise, materially diluting existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
This press release announces a registered direct offering of 750,000 Class A Ordinary Shares at $1.00 per share, generating approximately $750,000 in gross proceeds. The offering is structured as a registered direct offering (not a public offering) to institutional investors, which is a classic dilutive equity issuance. The disclosure explicitly references the shelf registration statement (Form F-3, File No. 333-291149) and prospectus supplement, confirming this is a registered securities offering that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
Goldman Sachs Private Credit Corp. completed an unregistered sale of Class I, S, and D shares totaling approximately $83.9 million to accredited investors and non-U.S. persons, exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-01
Item 3.02
Surf Air Mobility issued unregistered equity securities in connection with the debt refinancing, including shares of common stock issuable upon conversion of the $16.9 million convertible note and warrants issued to lenders, with the company agreeing to file a registration statement covering resale of warrant shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
CVC-PE Global Private Equity Fund, LP completed an unregistered private placement of limited partnership units totaling approximately $55.4 million on June 1, 2026, comprising 391,131 Class R-S Units, 120,221 Class R-I Units, and 455 Class C Units. The offering was conducted as part of the Fund's continuous private offering under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 8.01
Curbline Properties entered into an underwriting agreement on June 29, 2026, to offer and sell 10,000,000 shares of common stock on a forward basis, with the offering closing on July 1, 2026. The company also entered into forward sale agreements with forward purchasers. This is a material dilutive equity issuance—a forward offering of common stock that will result in the delivery of 10 million shares within approximately 18 months, with net proceeds intended for general corporate purposes including property acquisitions, debt repayment, and capital expenditures. The magnitude and structure (forward sale with underwriter involvement) are hallmarks of a material capital-raising event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
MSD Investment Corp. issued 9,574,468 shares of common stock for approximately $225.0 million on June 26, 2026, pursuant to subscription agreements with stockholders. The issuance was made under Section 4(a)(2) of the Securities Act and Regulation D, relying on accredited investor representations. This is a classic unregistered equity issuance under Item 3.02, representing a material capital raise that would affect investor assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 8.01
The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 1.01
INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 3.02
SunPower closed a $10 million share exchange on July 1, 2026, whereby convertible note holders exchanged cash interest payments due on the notes for 19.3 million shares of common stock issued under Section 4(a)(2) exemption. This unregistered equity issuance materially restructures the company's capital obligations by converting future cash interest payments into equity, significantly diluting existing shareholders.
View raw filing on EDGAR →